Conducting radiogenomic research - Do not forget careful consideration of the clinical data

Christian Nicolaj Andreassen*, Gillian C. Barnett, Johannes A. Langendijk, Jan Alsner, Dirk De Ruysscher, Mechtild Krause, Soren M. Bentzen, Joanne S. Haviland, Clare Griffin, Philip Poortmans, John R. Yarnold, ESTRO GENEPI Network

*Corresponding author for this work

Research output: Contribution to journalEditorialAcademicpeer-review

26 Citations (Scopus)

Abstract

The field of radiogenomics has evolved substantially over the last few years. Cooperative research groups have been established and high throughput genotyping has become increasingly feasible and affordable. Nevertheless, a number of clinical and dosimetric issues need to be carefully considered in order to fully exploit these new possibilities. (C) 2012 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 105 (2012) 337-340

Original languageEnglish
Pages (from-to)337-340
Number of pages4
JournalRadiotherapy and Oncology
Volume105
Issue number3
DOIs
Publication statusPublished - Dec-2012

Keywords

  • Normal tissue radiosensitivity
  • Predictive markers
  • Single nucleotide polymorphisms
  • GENOME-WIDE ASSOCIATION
  • NORMAL TISSUE-REACTIONS
  • RADIATION-THERAPY
  • END-POINTS
  • RADIOTHERAPY
  • TOXICITY
  • POLYMORPHISMS
  • RADIOSENSITIVITY
  • MECHANISMS
  • PATIENT

Cite this